CompoAtlas

Chronoveine Turbo Sticks

Food supplement declared in France, declaration No 2020-3-332

Chronoveine Turbo Sticks, from New Stefal Holding, is a food supplement declared in France. Status: withdrawal from the market announced for 4 November 2027. Main ingredients: Sambucus nigra 120 mg per day, Urtica dioica 100 mg per day, Ruscus aculeatus 100 mg per day, Citrus paradisi 100 mg per day, Foeniculum vulgare 30 mg per day. 2 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
New Stefal Holding
Status
Withdrawal from the market announced for 4 November 2027
Form
Stick
Daily dose
1 stick
Directions for use
Une fois par jour, diluer le contenu d'un stick dans un grand verre d'eau (250ml).
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Pregnant women
Objectives stated by the manufacturer (these are not authorised claims)
Blood and lymphatic circulation

Declaration 167894, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Sambucus nigra L.BaieExtrait sec aqueux120 mg
Urtica dioica L.FeuillePoudre (de plantes séchées ou broyées)100 mg
Ruscus aculeatus L.RacineExtrait sec hydroalcoolique100 mg
Citrus paradisi Macfad.FruitExtrait sec hydroalcoolique100 mg
Foeniculum vulgare Mill.FruitPoudre (de plantes séchées ou broyées)30 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
magnesium oxideMagnesium250 mg300 mg
pyridoxine hydrochlorideVitamin B612 mg2 mg

Additives

E330, E955

Other ingredients

maltodextrine, Jus de betterave

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Ne convient pas aux femmes enceintes ou qui allaitent et aux enfants de moins de 12 ans.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Sambucus nigra L.
    Read the warning, when it applies and the studies cited

    ELDER – SAMBUCUS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condition of application: Diaphoretic; Symptoms of colds, flus; Sinusitis, hay-fever; Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occur (Forster-Waldl et al. 2003).

    Sources cited by Health Canada (1)
    • Förster-Waldl E, Marchetii M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Jäger S, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Type I allergy to elderberry (Sambucus nigra) is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins. Clinical and Experimental Allergy 2003;33(2):1703-1710. PubMed

    Condition of application: All products except those making a diuretic claim.

    When using this product diuretic effect may occur (Bradley 1992; Winston and Kuhn 2008; Barnes et al. 2007; Hoffman 2003).

    Sources cited by Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines. 3rd edition. London (GB): The Pharmaceutical Press; 2007.
    • Winston D and Kuhn MA. Herbal Therapy & Supplements A Scientific and Traditional Approach. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Urtica dioica L.
    Read the warning, when it applies and the studies cited

    STINGING NETTLE JUICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products except nutritive tonics.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).

    Sources cited by Health Canada (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.

    Known adverse reactions

    Condition of application: All products except those making only a diuretic claim*.

    When using this product diuretic effect may occur.

    *Note: This statement can be removed from the label if a diuretic claim is included.

    Health Canada monograph dated 27 March 2026

    STINGING NETTLE - URTICA DIOICA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products except nutritive tonics.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).

    Sources cited by Health Canada (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.

    Known adverse reactions

    All products except those making only a diuretic claim*

    When using this product diuretic effect may occur.

    *Note: This statement can be removed from the label if a diuretic claim is included.

    Health Canada monograph dated 27 March 2026

  • Foeniculum vulgare Mill.
    Read the warning, when it applies and the studies cited

    BITTER FENNEL- FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Condition of application: Essential oil and Tincture.

    Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).

    Sources cited by Health Canada (1)
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).

    Sources cited by Health Canada (2)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
    • EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf

    Health Canada monograph dated 29 November 2024

    SWEET FENNEL -FOENICULUM VULGARE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (EMA 2024).

    Sources cited by Health Canada (1)
    • EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Chronoveine Turbo Sticks: composition and regulation”, https://compoatlas.com/en/supplements/products/167894-chronoveine-turbo-sticks, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line